Abcellera Biologics Inc ABCL

$11.12 -0.37 (-3.22%)

Valuation

Market cap
3,752,841,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,468,000
Avg volume
4,308,192
Day's range
$11.03 – $11.44
Shares out
326,618,000
Stochastic %K
16%
Beta
1.59
Analysts
Strong Buy
Price target
$17.92

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

flymetothemoon2 Nov 16, 8:43 PM 0 replies
erpy Nov 16, 8:34 PM
$ABCL Added 3 times today.
0 replies
flymetothemoon2 Nov 16, 8:19 PM 0 replies
flymetothemoon2 Nov 16, 8:01 PM
$ABCL $900,000,000 Million Plus in Cash 😮 🤯 not including Assets of Property 🤩 that we own!!
0 replies
shoc24 Nov 16, 7:38 PM
$ABCL is ranked #9 in healthcare momentum with a score of 87. I used Stock Meadow's scoring model. Build your own model and backtest it if you don't agree with mine.
0 replies
flymetothemoon2 Nov 16, 7:30 PM
$ABCL AbCellera’s Q3 slides on ABCL635 report complete resolution of VMS symptoms in 37 percent of participants, versus 2 percent on placebo. Stopping the symptom entirely, not just softening it, is a different bar to clear. Dare I say it…? Carl’s words not mine…
0 replies
maestrodarkhorse Nov 16, 7:23 PM
$ABCL Carl Hansen mentioned the DTC (Direct-to-Consumer) approach for the first time at this Jefferies Conference. It seems he sees a direct-to-consumer sales strategy for Abcl 635, like those used for Wegovy and Mounjaro, as advantageous for a young biotech company with a weak sales force.
2 replies
maestrodarkhorse Nov 16, 7:21 PM
$ABCL $ABCL Piper Sandler analyst Allison Bratzel raised the firm's price target on AbCellera to $20 from $12 and keeps an Overweight rating on the shares. With Q3 reporting largely wrapped up, the firm is updating estimates.
0 replies